TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39442958
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (arm B): four cycles of epirubicin and cyclophosphamide followed by four cycles of docetaxel (n=170)
Study: 39442958
Drug: Intensive adjuvant
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive adjuvant treatment (arm A)
Study: 39442958
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (arm B)
Study: 39443015
Drug: Antithrombotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic therapy (aspirin, P2Y)
Study: 39443081
Drug: Rifaximin 400
Normalized name: Rifaximin 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 400 mg twice daily for 8 weeks
Study: 39443403
Drug: Isavuconazole as
Normalized name: isavuconazole
DrugBank: Isavuconazole (DB11633)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isavuconazole as primary therapy
Study: 39443403
Drug: Isavuconazole as
Normalized name: isavuconazole
DrugBank: Isavuconazole (DB11633)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isavuconazole as salvage therapy
Study: 39443446
Drug: Ductal lavage
Normalized name: lovage oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ductal lavage with triamcinolone acetonide and antibiotics followed by observation (DL-OBS)
Study: 39443527
Drug: LPVr (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPVr (400 mg/100 mg twice daily)
Study: 39443527
Drug: LPVr +
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPVr + TLM (10 mg once daily)
Study: 39443527
Drug: LPVr +
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPVr + ATV (20 mg once daily)
Study: 39443659
Drug: Amiodarone (therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (therapeutic doses)
Study: 39443721
Drug: Accelerated intermittent
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated intermittent theta burst stimulation (aiTBS) during the acute phase (8 times daily for up to 10 days)
Study: 39443721
Drug: Accelerated intermittent
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated intermittent theta burst stimulation (aiTBS) during the tapering phase (2 treatment days per week for 2 weeks, followed by 1 treatment day per week for 2 weeks)
Study: 39443927
Drug: Lidocaine 1%
Normalized name: LIDOCAINE 1% LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1% (0.3 mL)
Study: 39443927
Drug: Papaverine HCl
Normalized name: papaverine HCl
DrugBank: Papaverine (DB01113)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Papaverine HCl 10 mg/mL (0.3 mL)
Study: 39443954
Drug: Ivabradine (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine (standard treatment for sepsis plus enteral ivabradine)
Study: 39443954
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment group (GS)
Study: 39443991
Drug: Blood biomarkers
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood biomarkers (surfactant protein-D, serine protease inhibitor A7, MMP-9)
Study: 39443991
Drug: Blood biomarkers
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood biomarkers (CC motif chemokine 11, vascular cell adhesion protein-1, adiponectin, carcinoembryonic antigen, MMP-9)
Study: 39444037
Drug: AL002 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL002 (single intravenous infusion)
Study: 39444037
Drug: AL002 (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL002 (weekly intravenous injections for 4 weeks in cynomolgus monkeys)
Study: 39444039
Drug: Anthracycline based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthracycline based chemotherapy
Study: 39444039
Drug: Ongoing clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ongoing clinical trials combining chemotherapy with immune checkpoint inhibitors
Study: 39444052
Drug: Prasugrel monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel monotherapy (3.75 mg/day)
Study: 39444052
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) with prasugrel and aspirin
Study: 39444052
Drug: No-aspirin group
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-aspirin group
Study: 39444571
Drug: Bovine milk-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine milk-based infant formula with added bovine MFGM (5 g/L) for 60 days
Study: 39445319
Drug: Tildrakizumab 100
Normalized name: tildrakizumab 100 mg/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tildrakizumab 100 mg at baseline, Week 4, and every 12 weeks thereafter to Week 52, with final assessment at Week 64.
Study: 39445319
Drug: Tildrakizumab treatment
Normalized name: Tildrakizumab
DrugBank: Tildrakizumab (DB14004)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tildrakizumab treatment
Study: 39445439
Drug: combination results
Normalized name: omega-3 acid ethyl esters (USP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination results
Study: 39445439
Drug: combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of neomer and ctDNA mutation-based results
Study: 39445609
Drug: perindopril/amlodipine 4/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: perindopril/amlodipine 4/5 mg
Study: 39445609
Drug: perindopril/amlodipine/indapamide 4/5/1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: perindopril/amlodipine/indapamide 4/5/1.25 mg
Study: 39446087
Drug: UGN-102 (mitomycin),
Approvals — FDA: no, EMA: no, PMDA: no
Description: UGN-102 (mitomycin), 6 weekly intravesical instillations
Study: 39446327
Drug: RT twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT twice daily to a dosage of 45 Gy for 3 weeks
Study: 39446327
Drug: RT once
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT once daily to a dosage of 70 Gy for 7 weeks
Study: 39446365
Drug: Intravenous nivolumab,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nivolumab, 3 mg/kg, every 2 weeks and ipilimumab, 1 mg/kg, every 6 weeks until disease progression, intolerable adverse events, or a maximum duration of 2 years.
Study: 39446377
Drug: Overall targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall targeted therapy cohort
Study: 39446605
Drug: HLX07 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLX07 monotherapy (1,000 mg IV Q2W)
Study: 39446605
Drug: HLX07 combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLX07 combined with serplulimab (200 mg IV day 1) and cisplatin (50 mg/m2)
Study: 39446648
Drug: internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: internet-based cognitive behavioral sex therapy (iCBST)
Study: 39446648
Drug: internet-based mindfulness-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: internet-based mindfulness-based sex therapy (iMBST)
Study: 39446736
Drug: Standard sacrospinous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard sacrospinous ligament suspension with sutures (SSLS)
Study: 39446746
Drug: COVID-19 treatment
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 treatment disruptions
Study: 39447049
Drug: Performance of
Normalized name: Perform
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Performance of instrumental activities of daily living (Lawton and Brody scale)
Study: 39447049
Drug: Dependence on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dependence on activities of daily living (Barthel scale)
Study: 39447053
Drug: F2 antigen
Normalized name: TRICOPHYTON ANTIGEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: F2 antigen or F2 antigen plus AS01 adjuvant (third dose)
Study: 39447517
Drug: SG001 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: SG001 240 mg every two weeks for 24 months or until disease progression, intolerable toxicities, or other study discontinuation criteria were met.
Study: 39447587
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of asthma medication in adolescents with severe symptoms
Study: 39447716
Drug: Intra-aortic balloon
Normalized name: somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-aortic balloon pumping (IABP) as an adjunct to veno-arterial (V-A) ECMO
Study: 39447871
Drug: Port Delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Port Delivery System with ranibizumab (100 mg/mL) Q24W
Study: 39447871
Drug: Monthly intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly intravitreal ranibizumab (0.5 mg)
Study: 39448077
Drug: Bilateral iTBS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral iTBS at 0-min intervals (once-daily)
Study: 39448218
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg micronised progesterone (mP) per day in continuous combination with 1 mg oestradiol
Study: 39448218
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg norethisterone acetate (NETA) per day in continuous combination with 1 mg oestradiol
Study: 39448218
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg micronised progesterone (mP) with 1 mg oestradiol
Study: 39448350
Drug: Avelumab first-line
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab first-line maintenance treatment
Study: 39448350
Drug: Avelumab first-line
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab first-line maintenance treatment followed by second-line enfortumab vedotin
Study: 39448350
Drug: Avelumab first-line
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab first-line maintenance treatment followed by platinum-based chemotherapy (PBC)
Study: 39448966
Drug: Spartalizumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spartalizumab (300 mg every 3 weeks) with platinum-doublet chemotherapy (PDC)
Study: 39448986
Drug: tixagevimab/cilgavimab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: tixagevimab/cilgavimab (300 mg)
Study: 39448999
Drug: Six-monthly PrEP
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Six-monthly PrEP dispensing with interim HIV self-testing (HIVST)
Study: 39448999
Drug: Standard-of-care three-monthly
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care three-monthly PrEP dispensing with clinic-based HIV testing
Study: 39449056
Drug: Functional exercise
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional exercise program (45-minute sessions, twice per week for 14 weeks)
Study: 39449979
Drug: CC-CLEAR scale
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-CLEAR scale
Study: 39450683
Drug: Stapokibart 300
Normalized name: Stapokibart
DrugBank: Stapokibart (DB18990)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stapokibart 300 mg every 2 weeks
Study: 39450683
Drug: Switching from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching from placebo to stapokibart 300 mg every 2 weeks
Study: 39450752
Drug: Microvascular inflammation
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microvascular inflammation without evidence of an antibody-mediated response
Study: 39450752
Drug: Antibody-mediated rejection
Normalized name: digoxin antibodies Fab fragments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody-mediated rejection
Study: 39450752
Drug: Probable antibody-mediated
Normalized name: digoxin antibodies Fab fragments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probable antibody-mediated rejection
Study: 39450934
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (6 weekly individual sessions)
Study: 39450934
Drug: Social attention
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Social attention control (6 weekly sessions)
Study: 39453356
Drug: Survodutide, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Survodutide, a dual glucagon and GLP-1 receptor agonist, administered subcutaneously once weekly
Study: 39453400
Drug: PLLA-SCA (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLLA-SCA (8 mL of sterile water + 1 mL of 2% lidocaine)
Study: 39453705
Drug: PSP Wellbeing
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSP Wellbeing Course (Internet-delivered cognitive behavioral therapy)
Study: 39453772
Drug: Iptacopan (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iptacopan (200 mg) twice daily for 24 months
Study: 39453950
Drug: Childhood Early
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Childhood Early Oral Aging Syndrome (CEOAS) index for the primary dentition
Study: 39454227
Drug: Enzalutamide 160
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide 160 mg once daily
Study: 39454281
Drug: IM cohort
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM cohort 1c (25/25/50 mg/m2 MWF)
Study: 39454281
Drug: IV cohort
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV cohort (25/25/50 mg/m2 MWF)
Study: 39455065
Drug: Filgotinib 200
Normalized name: nilotinib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgotinib 200 mg (de novo)
Study: 39455065
Drug: Filgotinib 100
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Filgotinib 100 mg (de novo)
Study: 39455065
Drug: Filgotinib 200
Normalized name: nilotinib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgotinib 200 mg (continued)
Study: 39455065
Drug: Filgotinib 100
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Filgotinib 100 mg (continued)
Study: 39456544
Drug: Empiric intravenous
Normalized name: aspirin / codeine phosphate Oral Tablet [Empirin with Codeine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric intravenous broad-spectrum antibiotics (IVBSA) for at least 48 h with PCT monitoring
Study: 39456544
Drug: PCT drop
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCT drop (defined as a reduction of 30% from baseline or a PCT level < 0.25 ng/mL)
Study: 39458142
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard IVF treatment)
Study: 39458156
Drug: Virtual Reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual Reality treatment
Study: 39458438
Drug: Caffeine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (2.5 mg/kg) administered twice during continuous wakefulness, last treatment 6.5 h before bedtime for recovery night.
Study: 39458438
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered twice during continuous wakefulness, last treatment 6.5 h before bedtime for recovery night.
Study: 39460719
Drug: Subcutaneous ocrelizumab
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous ocrelizumab (up to 1200 mg)
Study: 39460719
Drug: Subcutaneous ocrelizumab
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous ocrelizumab (920 mg)
Study: 39460719
Drug: Intravenous ocrelizumab
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous ocrelizumab (600 mg)
Study: 39461299
Drug: Apraglutide (once-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apraglutide (once-weekly subcutaneous injections)
Study: 39461302
Drug: MVA-BN-RSV vaccine
Normalized name: MVA-BN
DrugBank: Modified vaccinia ankara (DB15483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA-BN-RSV vaccine
Study: 39461739
Drug: Single-capsule BQT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-capsule BQT containing bismuth, metronidazole, tetracycline, and a proton pump inhibitor (PPI)
Study: 39461739
Drug: 10-day Single-capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day Single-capsule BQT (ScBQT)
Study: 39461739
Drug: 14-day BQT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day BQT using tetracycline plus metronidazole or amoxicillin plus either clarithromycin or metronidazole
Study: 39461792
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (1 g by slow intravenous injection within 15 min of umbilical cord clamping)
Study: 39461792
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching placebo by slow intravenous injection within 15 min of umbilical cord clamping)
Study: 39461860
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (three times per week using a diode laser device, starting on the first day of conditioning and continuing through day 3 post-transplant)
Study: 39461861
Drug: Inhaled isoflurane
Normalized name: isoflurane Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled isoflurane delivered via the Sedaconda ACD-S
Study: 39461864
Drug: Bosutinib 200
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bosutinib 200 mg QD for 24 weeks
Study: 39461864
Drug: Bosutinib 300
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bosutinib 300 mg QD for 24 weeks
Study: 39461878
Drug: AdAPT-001 plus
Normalized name: menthol 0.001 MG/MG [Lysine Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: AdAPT-001 plus a checkpoint inhibitor (CI)
Study: 39461878
Drug: Checkpoint inhibitor
Normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Sabatolimab (DB16322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Checkpoint inhibitor (CI)
Study: 39462122
Drug: Children with
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children with major alleles for SNP rs864537A > G in CD247 (AA genotype) born March-August
Study: 39462310
Drug: Selective Endothelin
Normalized name: endothelial growth factor A, vascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective Endothelin Receptor Antagonist SC0062
Study: 39462354
Drug: Telephone coaching
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone coaching (5 monthly calls from physiotherapist)
Study: 39462517
Drug: MBA-P01 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBA-P01 (20 U, five treatments over 16 months)
Study: 39462835
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy + short course of carbon ion radiotherapy (CIRT) followed by surgery and adjuvant chemotherapy
Study: 39463173
Drug: Vortioxetine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine (10 or 20 mg/day)
Study: 39463395
Drug: Sublingual microcirculatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual microcirculatory assessment on admission
Study: 39463748
Drug: Abemaciclib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib (150 mg twice daily for 2 years) plus endocrine therapy (ET)
Study: 39464181
Drug: Low-dose radiation
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose radiation (150 mGy 2x/week for 5 consecutive weeks)
Study: 39465217
Drug: Pritumumab (16.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pritumumab (16.2 mg/kg weekly)
Study: 39465257
Drug: Neoadjuvant sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant sintilimab (200 mg, day 1), anlotinib (10 mg, QD, PO, days 1-14), and platinum-based chemotherapy for 3 cycles, followed by adjuvant sintilimab (200 mg every 3 weeks).
Study: 39465257
Drug: Neoadjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant treatment phase.
Study: 39465324
Drug: PG2 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: PG2 500 mg
Study: 39465531
Drug: Mepolizumab 100
Normalized name: mepolizumab 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab 100 mg SC every 4 weeks
Study: 39465531
Drug: Mepolizumab 40
Normalized name: MEPOLIZUMAB 40MG/0.4ML INJ SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab 40 mg SC every 4 weeks (for bodyweight <40 kg)
Study: 39465752
Drug: Biomimetic oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biomimetic oral appliance therapy (BOAT) device
Study: 39465888
Drug: Lactoferrin (rhLF)
DrugBank: Lactoferrin (DB16555)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactoferrin (rhLF) at two doses
Study: 39466236
Drug: Vitamin K2
Normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K2 (menaquinone 7), 180 μg, daily for 8 weeks
Study: 39466253
Drug: Acetazolamide Therapy
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide Therapy
Study: 39466933
Drug: KSL-W chewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: KSL-W chewing gum (30 mg dose)
Study: 39466933
Drug: KSL-W chewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: KSL-W chewing gum (doses ≥ 20 mg)
Study: 39466933
Drug: KSL-W chewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: KSL-W chewing gum (2-100 mg single doses)
Study: 39466933
Drug: KSL-W chewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: KSL-W chewing gum (4-75 mg multiple doses)
Study: 39467892
Drug: Platelet-rich fibrin
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich fibrin (PRF) treatment of sockets after third molar removal
Study: 39467892
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment of sockets after third molar removal
Study: 39468592
Drug: Ravulizumab treatment
Normalized name: ravulizumab
DrugBank: Ravulizumab (DB11580)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ravulizumab treatment